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Abstract
Background: The transcription factor activator protein-1 (AP-1) has been implicated in a large variety of
biological processes including oncogenic transformation. The tyrosine kinases of the epidermal growth
factor receptor (EGFR) constitute the beginning of one signal transduction cascade leading to AP-1
activation and are known to control cell proliferation and differentiation. Drug discovery efforts targeting
this receptor and other pathway components have centred on monoclonal antibodies and small molecule
inhibitors. Resistance to such inhibitors has already been observed, guiding the prediction of their use in
combination therapies with other targeted agents such as RNA interference (RNAi). This study examines
the use of RNAi and kinase inhibitors for qualification of components involved in the EGFR/AP-1 pathway
of ME180 cells, and their inhibitory effects when evaluated individually or in tandem against multiple
components of this important disease-related pathway.
Methods: AP-1 activation was assessed using an ME180 cell line stably transfected with a beta-lactamase
reporter gene under the control of AP-1 response element following epidermal growth factor (EGF)
stimulation. Immunocytochemistry allowed for further quantification of small molecule inhibition on a
cellular protein level. RNAi and RT-qPCR experiments were performed to assess the amount of
knockdown on an mRNA level, and immunocytochemistry was used to reveal cellular protein levels for
the targeted pathway components.
Results: Increased potency of kinase inhibitors was shown by combining RNAi directed towards EGFR
and small molecule inhibitors acting at proximal or distal points in the pathway. After cellular stimulation
with EGF and analysis at the level of AP-1 activation using a β-lactamase reporter gene, a 10–12 fold shift
or 2.5–3 fold shift toward greater potency in the IC50 was observed for EGFR and MEK-1 inhibitors,
respectively, in the presence of RNAi targeting EGFR.
Conclusion: EGFR pathway components were qualified as targets for inhibition of AP-1 activation using
RNAi and small molecule inhibitors. The combination of these two targeted agents was shown to increase
the efficacy of EGFR and MEK-1 kinase inhibitors, leading to possible implications for overcoming or
preventing drug resistance, lowering effective drug doses, and providing new strategies for interrogating
cellular signalling pathways.
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Background
Cellular processes such as proliferation, differentiation,
and death are regulated by signal transduction pathways
which commonly exert their function through receptor
mediated activation. The discovery in 1978 that the v-Src
oncogene was a protein kinase led to a "cascade" of
research into the role of kinases in cell-signalling path-
ways, and the subsequent finding that human cancer can
result from the activity of nonviral, endogenous onco-
genes, a major portion of which code for protein tyrosine
kinases (PTKs) [1,2]. The epidermal growth factor recep-
tor (EGFR) is a tyrosine kinase which acts as a master
switch leading to activation of the transcription factor,
activator protein-1 (AP-1), and other related pathways.
The receptor itself is composed of extracellular, trans-
membrane, and tyrosine kinase domains. Ligand binding
elicits a conformational change of the extracellular
domain leading to receptor dimerization and subsequent
transphosphorylation of intracellular domain tyrosines.
The phosphorylated tyrosines act as binding sites for sig-
nal transducers initiating a series of kinase actions result-
ing in cellular proliferation and differentiation [3-5].
Aberrant signalling occurring from EGFR results in its con-
version into an oncoprotein, and the consequent mal-
function of cellular signalling networks leads to the
development of cancers and other proliferative diseases.
EGFR and its ligands are involved in over 70% of all can-
cers [[4,6], and [7]].
Hidaki, et.al. in the early 1980's discovered the first pro-
tein-kinase inhibitors, and established the principle of
changing chemical structure to elicit different kinase inhi-
bition specificity [8]. Drug development has followed the
lead of the academic community in developing novel
inhibitory compounds at points along these disease-
related pathways. The protein kinase target class is now
the second largest group of drug targets behind G-protein-
coupled-receptors [3]. Kinases of the Tyrosine and Serine/
Threonine family have been targeted successfully by
small-molecule inhibitors and monoclonal antibodies,
with many undergoing human clinical trials or success-
fully launched as therapeutic entities [9-13].
Acquired resistance to kinase-targeted anticancer therapy
has been documented, and most extensively studied with
imatinib (Gleevec™), an inhibitor of the aberrant BCR-
ABL kinase, in chronic myelogenous leukemia [14].
Resistance has also occurred in EGFR-targeted inhibitor
therapy using gefitinib (Iressa™) and erlotinib (Tarceva™).
Mutations occurring in the catalytic domain of the recep-
tor have been implicated in this resistance, but cannot
account for all resistance seen to these small molecule
inhibitors, indicating other mechanisms are involved in
the resistance seen to date [15,16]. Therefore, multiple
strategies will be necessary to overcome the observed
resistance to these new molecularly targeted therapies, as
well as methods to predict their efficacy.
Most kinase inhibitors target the ATP-binding site com-
mon to all kinases, and can bind multiple kinases [17].
This generates an inability to predict compound specifi-
city for a particular kinase, and the subsequent need to
analyze large numbers of kinases through a screening or
profiling approach. Data from these in vitro assays allow
the researcher to predict clinical uses for inhibitors and
possible offsite target effects. Studies using purified kinase
and substrate are dependent on ATP concentration used,
and the apparent Km for ATP can differ between kinases.
This can lead to problems in the development of small
molecule inhibitors based on competition at the ATP-
binding site of a kinase, as the ATP concentration in vivo
may differ greatly from that used in vitro. In addition,
kinase activity studies in a purified setting may use
domains of proteins and peptide substrates, which can
lead to erroneous interpretation of the true nature of
kinase activity and/or inhibition. The in vivo studies using
Western blot analysis also can be difficult to interpret due
to the need to use a protein preparation from a cellular
lysate, and inherent variability when using antibodies for
Western blot analysis. Small changes in any step of the
protocol could lead to differences in interpretation of the
results. For these reasons, and the need for strategies to
prevent or overcome resistance formation in malignan-
cies, we have used an in vitro and functional cellular assay
approach to study the EGFR/AP-1 signal transduction
pathway. AP-1 activation through EGFR was assessed
using a β-lactamase reporter gene assay, and served as a
model for inhibition of pathway components on a func-
tional cellular level. Kinase profiling using full length
EGFR and peptide substrates was used in parallel for con-
firmation and specificity of inhibition. The knockdown of
qualified targets in the EGFR/AP-1 pathway was further
studied by immunocytochemistry, allowing for assess-
ment on a cellular protein level. Following qualification
of targets in this cancer-related pathway, a functional cel-
lular assay was used to analyze the potential therapeutic
benefit of combining RNAi and kinase inhibitors against
EGFR and MEK-1 in the AP-1 activation pathway of a
human cervical cancer cell line.
Methods
AP-1-bla ME180 CellSensor™cell line
An AP-1 response element (TGACTAA, 7X) was inserted
into the MCS of the β-lactamase lentiviral reporter vector
using Gateway® technology according to the manufac-
turer's instructions (Invitrogen, Carlsbad, CA). The virus
created from this vector was used to transduce ME180
cells [18] according to manufacturer's instructions (Invit-
rogen, Carlsbad, CA). Following a one day incubation, the
cells were split and placed in media with Blasticidin (5 ug/BMC Cancer 2005, 5:125 http://www.biomedcentral.com/1471-2407/5/125
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ml) for 3–4 days. Cells were then washed with phosphate
buffered saline (PBS), refed, and further selected for seven
to ten days in media containing Blasticidin. Flow cytome-
try was used to select for β-lactamase expressing cells
according to previously published protocols [19].
EGF ligand stimulation of AP-1-bla ME180
AP-1-bla ME180 cells were plated in 96 well plates at a
density of 20,000–25,000 cells/well in DMEM with 1 mM
sodium pyruvate, 25 mM HEPES, 0.1 mM non-essential
amino acids (Invitrogen Gibco, Grand Island, NY) plus
1% fetal bovine serum (FBS) and incubated overnight at
37°C with 5% CO2. The following day rhEGF (Calbio-
chem, San Diego, CA) was diluted in media with 1% FBS
at desired concentrations, and cells incubated at 37°C
with 5% CO2 for 5 hours. EGF treatment was performed at
n = 8.
β-lactamase reporter analysis
β-lactamase reporter gene expression was determined
using the LiveBLAzer™ FRET B/G assay kit (Invitrogen
Drug Discovery, Madison, WI) according to manufac-
turer's instructions.
Inhibitor treatment of AP-1-bla ME180
Small molecule inhibitors (Calbiochem, San Diego, CA)
were diluted in cell culture media at the desired concen-
tration and preincubated with the cells for 30 minutes at
37°C with 5% CO2. EGF ligand stimulation was per-
formed as indicated above followed by β-lactamase
reporter analysis. DMSO was used as the negative control,
per its use as the compound reconstitution medium. Final
DMSO concentration in the medium was 0.05% for both
compounds and negative controls.
RNAi design and transfection of AP-1-bla ME180
dsRNAi Stealth™ oligos were designed against EGFR. The
following sequences were used for the oligos:
EGFR: Sense 5' UUA GAU AAG ACU GCU AAG GCA
UAG G 3'
Anti-Sense 5' CCU AUG CCU UAG CAG UCU UAU CUA
A 3'
AP-1-bla ME180 cells were plated at a concentration of
10,000 cells/well in a 96 well plate and incubated over-
night at 37°C with 5% CO2. AP-1-bla ME180 cells were
transfected with 50 nM dsRNAi Stealth™ oligos and 2 µg/
ml Lipofectamine 2000 according to manufacturer's sug-
gestions (Invitrogen, Carlsbad, CA). mRNA was extracted
from transfected cells 24 hours post transfection and
EGFR expression levels determined by RT-qPCR using
light upon extension (LUX™) primer sets (Invitrogen,
Carlsbad, CA) for the target of interest and cyclophilin as
a normalization control. Percent knockdown of the tar-
geted message was determined as a ratio of target versus
cyclophilin control.
Functional cellular analysis of the effect of RNAi knock-
down was studied using the AP-1-bla ME180 CellSensor.
The cells were transfected with ds RNAi oligos as above
and incubated for various lengths of time prior to EGF
stimulation for 5 hours and subsequent quantitation of β-
lactamase using the LiveBLAzer FRET B/G assay kit
(Invitrogen).
Immunocytochemistry for cellular protein knockdown and 
phosphorylation status of EGFR
AP-1-bla ME180 cells were analyzed for EGFR knockdown
at a cellular protein level following RNAi treatment. Cells
were transfected with dsRNAi oligos as in the functional
cellular studies above and incubated for ~60 hrs. The cells
were then fixed with 4% Paraformaldehyde for 30 min-
utes at 22°C, followed by permeabilization in PBS +
0.25% Triton X-100 for 5 mins at 22°C. Blocking of
antigen binding sites was performed with PBS + 2% FBS
for 2 hours at 22°C with rocking. Cells were washed twice
with PBS + 2% FBS, then incubated with rabbit anti-phos-
pho-EGFR (Tyr1086) or mouse anti-EGFR (31G7) pri-
mary antibody (Invitrogen Zymed, San Francisco, CA) at
1:100 concentration and 1:25 concentration respectively
in PBS + 1% FBS for 1 hour at 22°C with rocking. Follow-
ing primary antibody incubation, the cells were washed
twice with PBS + 1% FBS at 22°C with rocking. The sec-
ondary antibodies goat anti-rabbit IgG (H+L) Alexa Fluor®
488 and goat anti-mouse IgG (H+L) Alexa Fluor® 594
(Invitrogen Molecular Probes, Eugene, OR) were used at 1
µg/mL concentration in PBS + 1% FBS, and incubated at
22°C with rocking. Cells were washed three times with
PBS + 1% FBS followed by addition of PBS + 10% glycerol
for assay and storage. A Zeiss Axiovert 25CFL microscope
with a FITC filter set (excitation D480/30X, emission
D535/40 M, Chroma Technology Corporation, Rocking-
ham VT) for Alexa 488, and a Texas Red filter set (excita-
tion D560/40X, emission D630/60 M, Chroma
Technology Corporation, Rockingham VT) for Alexa 594
was used for imaging of cells. Quantitation of knockdown
was done using a Tecan Safire® instrument using excitation
wavelength of 485/7.5 nm and emission wavelength of
510/7.5 nm for the Alexa 488 labelled secondary antibody
and excitation wavelength of 590/7.5 nm and emission
wavelength of 615/7.5 nm for the Alexa 594 labelled sec-
ondary antibody.
Immunocytochemistry for EGFR phosphorylation 
following kinase inhibitor treatment
AP-1-bla ME180 cells were treated with kinase inhibitors
as outlined above. Immunocytochemistry using
appropriate phospho-specific antibodies was performedBMC Cancer 2005, 5:125 http://www.biomedcentral.com/1471-2407/5/125
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as in the RNAi experiments to analyze EGFR
autophosphorylation.
Combining RNAi and kinase inhibitors on the AP-1-bla 
ME180 CellSensor
AP-1-bla  ME180 cells were treated with 50 nM RNAi
against EGFR as in experiments outlined above. Only one-
half of a 96 well plate was treated, while the other half was
mock treated with Lipofectamine™ 2000 (Invitrogen,
Carlsbad, CA) alone. At 60 hours the cells were treated
with a dilution series of AG1478 or U0126 as outlined
above. Cells were then stimulated with EGF and the result-
ing  β-lactamase readout was analyzed using GraphPad
Prism® to determine IC50 values. Controls for RNAi trans-
fection (Med GC; 40–50% GC nucleotide content), EGFR
knockdown (EGFR RNAi), and β-Lactamase knockdown
(β-Lac) were used to set standards for transfection, single
treatment, and maximal effects respectively.
Kinase profiling of compounds used in functional cellular 
assays
Small molecule compounds used in the cellular assays
were profiled in the SelectScreen™ Kinase Profiling Service
(Invitrogen Drug Discovery Solutions, Madison, WI). This
service utilizes the Z'-Lyte technology assay platform [21]
where the biochemical assays were performed at a final
concentration of 1 µM compound in 0.1% DMSO and an
ATP concentration of Km, app for the EGFR protein. The
assays were analyzed on a Tecan Safire2® detection instru-
ment. The percent inhibition values were calculated using
XL fit 4.0 by ID-BS.
Results
ME180 EGFR/AP-1 signal transduction pathway is 
responsive to EGF stimulation
In order to use the AP-1-bla ME180 CellSensor as a model
system for combining targeted agents against components
of a cancer-related pathway, we determined the dose-
dependent response of the pathway to EGF stimulation.
The EC50 was determined to be 0.31 ng/mL from the
blue:green ratiometric readout of the β-lactamase assay
(Figure 1A). Imaging capabilities made possible with the
β-lactamase reporter system allow for microscopic visual-
ization of reporter enzyme activity due to cleavage of the
FRET-based substrate (Figure 1B). To maximize the assay
window while maintaining sensitivity to inhibition by
putative inhibitors, an EC80 concentration of 1 ng/ml EGF
was used to stimulate pathway response in inhibition
assays.
EGFR/AP-1 signal transduction can be inhibited at multiple 
points in the pathway
The commercial availability of known small molecule
kinase inhibitors allowed for the study of their potency in
our cellular system. Prior to analyzing efficacy in a func-
tional cellular assay, we tested their inhibition of EGFR in
a biochemical assay using Z'-LYTE, a FRET-based
platform.
The small molecule compounds are structurally related
with some targeting the ATP binding site of the kinase
(AG1478, CL387785, PD153035, SB202190) [20], and
others targeting the tyrosine substrate binding site
(AG490, AG183) [4,22]. U0126 acts in the unique man-
ner of blocking activation of MEK through a mechanism
independent of the ATP binding site [12,23]. The kinase
inhibitors tested show a spectrum of inhibition against
EGFR (Figure 2), and correlate well with published results
of inhibitor specificity [17].
The inhibitors were next tested for their effectiveness in
inhibiting the EGFR/AP-1 pathway in a functional cellular
assay. Initial analysis was performed with an inhibitor
concentration of 500 nM. Results indicate the CL387785,
PD153035, and AG1478 compounds strongly inhibit AP-
1 gene activation (Figure 3A), indicating that targeting of
EGF mediated activation in ME180AP-1 CellSensor Figure 1
EGF mediated activation in ME180AP-1 CellSensor. 
EGF effectively stimulated the EGFR/AP-1 pathway in ME180 
cervical cancer cells. Cells expressing β-lactamase were 
detected using a fluorescent plate reader (Panel A) or under 
fluorescent microscopy (Panel B). β-lactamase was measured 
using Invitrogen's LiveBLAzer™ FRET B/G assay. Ratios rep-
resent the mean of (± SEM) eight independent data points (n 
= 8).
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EGFR leads to a potent reduction in AP-1 gene expression
in ME180 EGF stimulated cells. AG183 shows no inhibi-
tion at 500 nM and also showed no inhibition of EGFR in
the biochemical assay (Figure 2). The U0126 compound,
which targets MEK-1, also shows inhibition of the EGFR/
AP-1 pathway (Figure 3A), an expected result when target-
ing another component of the EGFR/AP-1 pathway. The
p38 MAP kinase inhibitor SB202190 shows no inhibition
of the pathway in the AP-1-bla ME180 CellSensor as could
be predicted based on known pathway components. The
live cell assay format allows for imaging and further con-
firmation of the inhibition shown in the quantitative
panel (Figure 3B).
The inhibitors that tested positive for inhibition in the
functional cellular assay at a 500 nM concentration were
further studied in a dose response manner. Inhibitor
potency could be assigned through IC50  values deter-
mined on a cellular pathway level. The EGFR inhibitors
CL387785, PD153035, and AG1478 show increased effi-
cacy of pathway inhibition when compared to U0126, as
might be expected when targeting the initial component
of this receptor linked pathway (Figure 4A, B, and 4C).
Cellular phosphorylation of EGFR on a cellular protein 
level matches reporter gene results
Confirmation on a cellular protein level of the results
obtained using kinase inhibitors on the EGFR/AP-1 path-
way in a cell-based reporter readout was obtained through
immunocytochemistry. Inhibition of autophosphoryla-
tion was shown by using antibodies specific for the phos-
phorylated tyrosine-1086 of EGFR. PD153035 showed
strong inhibition of EGFR autophosporylation, while
AG183 did not (Figure 5A and 5B) validating the results
seen in the functional cellular assay (figure 4).
RNAi qualifies EGFR as a target for AP-1 pathway 
inhibition
dsRNAi towards EGFR was shown to knockdown the total
amount of EGFR present as well as the
autophosphorylation of the receptor. Analysis of knock-
Biochemical assay results with kinase inhibitors Figure 2
Biochemical assay results with kinase inhibitors. Per-
cent inhibition values determined by using the Z'-LYTE tech-
nology platform (Invitrogen), and single point concentration 
testing (1 µM) with two independent data points (n = 2). 
Small molecule compounds CL387785, PD153035, and 
AG1478 show strong inhibition of the EGFR, while others 
tested exhibit none.
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Kinase inhibitors block activation at multiple points 
in EGFR/AP-1 pathway. Inhibitors decrease the response 
of the AP-1-bla ME180 CellSensor when stimulated with 
EGF. β-lactamase was measured using Invitrogen's Live-
BLAzer™ assay (Panel A). Percent inhibition is determined in 
comparison to untreated sample and represents the mean of 
(± SEM) eight independent data points (n = 8). Photomicro-
graphs of cells were obtained under fluorescent microscopy 
(Panel B).
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down was analyzed by RT-PCR demonstrating an ~80%
knockdown on an mRNA level (Figure 6A). Immunocyto-
chemistry performed on RNAi treated AP-1-bla  ME180
cells shows a knockdown of EGFR on a cellular protein
level with a concomitant loss of autophosphorylation of
the receptor (Figure 6B and 6C). Analysis of the effect of
RNAi knockdown in a functional cellular assay confirmed
the essential role of EGFR in the activation of AP-1 (Figure
6D). In addition, lower receptor levels result in less path-
way response, and the stronger effect on AP-1 activation
correlates with RNAi incubation time. Additional controls
using a low GC (30–40% GC content) dsRNAi oligo and
dsRNAi oligos targeting genes not involved in the EGFR/
AP-1 pathway (NF-κB, IKK-α) show no effect on a cellular
protein level or in a functional cellular assay (data not
shown).
Combining EGFR RNAi with AG1478 or U0126 increases 
the potency of the kinase inhibitors against AP-1 
activation
To determine whether there were additive effects, which
could be relevant in therapeutic efficacy and prevention of
drug resistance (15,16, and 24), we performed experi-
ments using small molecule inhibitors in combination
with RNAi. U0126, a known MEK-1 inhibitor, exhibits an
IC50 of 543 nM when used in isolation on the AP-1 cell
line. Upon combination with RNAi against EGFR, the IC50
for the MEK-1 inhibitor shifts 2.5–3 fold more potent to
192 nM (Figure 7A, B, and 7C). AG1478, an EGFR inhib-
itor, exhibits an IC50 of 18 nM in isolation, but shifts to
1.5 nM when used in tandem with RNAi targeting EGFR
(Figure 7D, E, and 7F). The results indicate the validity of
using a functional cellular assay for the preclinical analy-
sis of putative benefits when combining kinase inhibitors
with other targeted agents of signal transduction pathways
related to cancer.
Discussion
Molecular targeted therapies against signalling pathway
components involved in cancer have arrived in the clinic,
and drug discovery efforts are increasing in this evolving
area [[3,9,11,13,24], and [25]]. The growth of screening
for small molecule compounds which act as kinase inhib-
itors has led to their becoming the second most targeted
group of druggable entities after G-protein-coupled recep-
tors [26].
Modulation of kinase activity can be accomplished by
strategies other than inhibition of phosphorylation activ-
ity through the blocking of ATP binding. Such methods
Potency of individual inhibitors towards kinases in the AP-1 pathway determined in a dose response manner Figure 4
Potency of individual inhibitors towards kinases in the AP-1 pathway determined in a dose response manner. 
Inhibitors were used in a dose response manner on the AP-1-bla ME180 CellSensor, and β-lactamase measured using Invitro-
gen's liveBLAzer™ FRET B/G assay (Panels A and B). IC50 determinations were performed using GraphPad Prism® and values 
shown with images of inhibitors at 0.2 µM concentration (Panel B).
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include disruption of protein-protein interactions and the
knockdown or downregulation of kinase gene expression
by antisense or RNA interference approaches [16,24]. The
need for multiple approaches for therapies targeting
kinases can be seen in the reports of resistance towards the
recently launched kinase inhibitors gefitinib (Iressa™) and
imatinib (Gleevec™), which inhibit the EGFR and Bcr-Abl
kinase respectively [14,27]. Strategies implemented for
overcoming or preventing this resistance have included
chemical modifications of the inhibitor compound using
a rational drug design strategy to increase the potency
against the targeted kinase. The ATP binding site of
kinases has proven to be a "hot spot" for kinase mutations
and includes a "gatekeeper" region shown to be difficult
to block with inhibitors and their new more potent deriv-
atives. Recent work has been published on inhibitors tar-
geting the substrate binding site of the Bcr-Abl kinase [28],
which seem to inhibit wild-type and all imatinib-resistant
kinase domain mutations, including the "gatekeeper"
mutation [29]. These approaches have proven successful
for imatinib and will undoubtedly work in the near term
for other small molecule inhibitors, but experience sug-
gests the possibility of further mutations leading to
increased resistance [[15,16], and [24]].
Blockade of one kinase alone might not be sufficient to
achieve needed pathway inhibition, and so targeting of
multiple kinases could be more promising in terms of
efficacy and prevention of resistance. This type of combi-
natorial therapeutic approach has become the standard
for HIV treatment to maximize potency, minimize
toxicity, and diminish the risk for resistance development
[30]. Targeted compounds could be used together or in
combination with toxic agents such as chemotherapy or
ionizing radiation, as well as with other novel agents. This
approach has proven successful in recent studies using
chemotherapeutic agents or ionizing radiation in
combination with kinase inhibitors [[31-33] and [34]].
However, given the rapidly growing number of inhibitory
agents and an exponential number of possible
combinations, it will not be possible to test all such
groupings in a clinical trial setting [16,24]. The need for
predictive preclinical models allowing for the choice of
which studies to advance through the drug discovery proc-
ess led to the experiments outlined in this paper with
RNAi and the kinase inhibitors U0126 and AG1478.
First, in order to establish a functional cellular model for
investigation of the EGFR/AP-1 pathway we built a stable
cell line responsive to EGF stimulation. Kinase inhibitors
and RNAi analysis established components that were
involved in the functional response of the EGFR/AP-1
pathway that could be inhibited by molecularly targeted
agents.
Biochemical analysis of EGFR inhibition using the same
small molecule inhibitors further supported our cellular
results and demonstrated the importance of complimen-
tary approaches when analyzing signal transduction path-
ways. Inhibitors such as U0126 inhibit the functional
response of the AP-1 pathway as shown in the cellular
reporter readout, but work at a level independent of EGFR
inhibition determined by in vitro assays.
Autophosphorylation of EGFR shows similar inhibition pro- file as the AP-1-bla ME180 functional cellular assay Figure 5
Autophosphorylation of EGFR shows similar inhibi-
tion profile as the AP-1-bla ME180 functional cellular 
assay. Immunocytochemistry with phospho-specific antibod-
ies demonstrates the same inhibition profile as the AP-1 acti-
vation assay performed using the ME180 CellSensor. 
Fluorescence was measured from the Alexa fluor 488 and 
594 labelled secondary antibodies used for detection (Panel 
A). Percent inhibition was determined in comparison to 
untreated sample and represents the mean of (± SEM) eight 
independent data points (n = 8). Images were obtained from 
the Alexa fluor 488 labelled secondary antibody under fluo-
rescent microscopy (Panel B).
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RNAi analysis and immunocytochemistry further demon-
strated the essential role EGFR plays at the beginning of
the AP-1 activation cascade. Showing that inhibition or
knockdown of the receptor leads to the functional results
observed in the cellular assay model, led us to analyze
combinatorial effects of using RNAi and kinase inhibitors
in tandem. When the targeted agents were used together,
an increased potency of the inhibitors was observed. This
finding demonstrates the use of a cellular reporter system
to predict the cocktail effects of a growing number of
targeted agents against cell signalling components
involved in cancer.
Conclusion
Our results demonstrate the essential role for EGFR in AP-
1 activation when analyzed using an ME180 cervical
cancer cell line. Confirmation of "druggable" targets was
shown using the parallel approach of known kinase
inhibitors and RNA interference. An immunocytochemis-
try approach using phospho- and pan-specific EGFR anti-
bodies strengthened the argument for the use of the AP-1-
bla ME180 cell line as a viable model for the analysis of a
combinatorial targeted agent approach to cancer-related
pathways. Results obtained combining RNAi toward
EGFR and small molecule inhibitors of MEK-1 and EGFR
indicate a beneficial effect on EGFR/AP-1 pathway inhibi-
tion. This cellular model approach could lead to further
studies combining kinase inhibitors with other targeted
agents, and suggests possible implications for screening of
compound libraries to uncover novel pathway inhibitors.
Abbreviations
AP-1 = Activator Protein 1, bla = beta-lactamase, EGFR =
Epidermal Growth Factor Receptor, MEK1 = Mitogen Acti-
vated Protein Kinase Kinase 1, Phosphate Buffered Saline
PBS, PTKs = Protein Tyrosine Kinases, RNAi = RNA
interference.
Knockdown by RNAi qualifies EGFR involvement in ME180 AP-1 CellSensor pathway Figure 6
Knockdown by RNAi qualifies EGFR involvement in ME180 AP-1 CellSensor pathway. AP-1-bla ME180 cells trans-
fected with RNAi targeting EGFR were analyzed by RT-qPCR (Panel A). EGFR mRNA expression is knocked down ~80% as 
compared to a non-specific control (Med GC). Results are represented as a ratio using cyclophilin as a control. Cells RNAi 
treated with oligos specific for EGFR show a reduced level of EGFR protein on the cell surface including a loss of autophospho-
rylation (Panels B and C). RFU represent measurement of the Alexa fluor 488 and 594 labelled secondary antibodies used for 
detection of the phospho and pan EGFR antibodies and represent the mean of (± SEM) eight independent data points (n = 8). 
RNAi treated AP-1-bla ME180 cells also exhibit a knockdown of AP-1 activation when EGF stimulated and analyzed at different 
timepoints (Panel D). Normalized response represents the amount of AP-1 gene activation present when compared with a 
non-specific control (Med GC), and represent the mean of (± SEM) eight independent data points (n = 8).
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Combining RNAi toward EGFR and the kinase inhibitors U0126 and AG1478 increases the potency of the small molecule  compounds Figure 7
Combining RNAi toward EGFR and the kinase inhibitors U0126 and AG1478 increases the potency of the 
small molecule compounds. Small molecule kinase inhibitors shown to have inhibitory properties in the AP-1 CellSensor 
assay were used in tandem with RNAi. RNAi targeting the EGFR was kept constant while U0126 targeting MEK-1 kinase (Panel 
A) and AG1478 targeting EGFR (Panel C) were used in a dose response manner to examine potency effects of the combined 
treatment. The shift in IC50 indicates the "cocktail" effect seen with the tandem treatment.
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